ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,233Medicare Part D Prescriptions Filled, Including Refills

Rank: 131 out of 617

$447K Total Retail Price of All Prescriptions

Rank: 128 out of 617

304 Patients Receiving at Least One Drug in Part D
87%Patients 65 Years and Older
30% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 304 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

20% of this provider’s 304 patients filled at least one prescription for a schedule three drug, compared to an average of 11%.

Risky Drugs to Seniors

2% of this provider’s 8,213 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$48 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

30 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
HYDROCODONE-ACETAMINOPHEN 371 316 S3 1 8
LEVOTHYROXINE SODIUM 359 326 2 1
OMEPRAZOLE 344 301 3 3
FUROSEMIDE 335 315 4 4
METFORMIN HCL 245 213 5 9
LISINOPRIL 238 220 6 5
SIMVASTATIN 232 227 7 2
METOPROLOL TARTRATE 218 205 8 11
METOPROLOL SUCCINATE 206 193 9 12
POTASSIUM CHLORIDE 201 177 10 10
ALLOPURINOL 172 139 11 27
WARFARIN SODIUM 165 150 12 7
GLIPIZIDE ER 164 149 13 94
HYDROCHLOROTHIAZIDE 161 155 14 13
AMLODIPINE BESYLATE 160 157 15 6
ATORVASTATIN CALCIUM 148 129 16 14
MELOXICAM 123 116 17 24
ATENOLOL 118 106 18 17
CRESTOR 108 106 19 28
ENALAPRIL MALEATE 106 99 20 34
GABAPENTIN 92 58 21 16
SERTRALINE HCL 86 84 22 20
CIPROFLOXACIN HCL 86 82 22 60
LOSARTAN POTASSIUM 83 56 24 22
TRAMADOL HCL 79 66 25 15
PREDNISONE 78 78 26 31
ALENDRONATE SODIUM 73 73 27 25
GEMFIBROZIL 73 61 27 105
RAMIPRIL 69 69 29 67
MECLIZINE HCL 68 68 30 150
DOXAZOSIN MESYLATE 67 67 31 79
CLONIDINE HCL 66 58 32 55
AMITRIPTYLINE HCL 63 43 R 33 56
TRIAMTERENE-HCTZ 63 50 33 47
CARBIDOPA-LEVODOPA 61 61 35 69
FENTANYL 61 40 S2 35 45
AMIODARONE HCL 60 60 37 129
NITROGLYCERIN PATCH 57 57 38 198
CYMBALTA 57 19 38 49
GLIPIZIDE 56 56 40 82
RISPERIDONE 55 42 41 71
SULFAMETHOXAZOLE-TRIMETHOPRIM 54 51 42 91
CARVEDILOL 54 50 42 19
CITALOPRAM HBR 53 53 44 18
LANTUS 52 52 45 39
NAMENDA 52 52 45 35
SYNTHROID 52 52 45 59
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 8, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.